GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (STU:AB3A) » Definitions » Debt-to-Asset

Sarepta Therapeutics (STU:AB3A) Debt-to-Asset : 0.39 (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sarepta Therapeutics Debt-to-Asset?

Sarepta Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €83 Mil. Sarepta Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1,177 Mil. Sarepta Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €3,244 Mil. Sarepta Therapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.39.


Sarepta Therapeutics Debt-to-Asset Historical Data

The historical data trend for Sarepta Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Debt-to-Asset Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.36 0.37 0.52 0.43

Sarepta Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.43 0.43 0.40 0.39

Competitive Comparison of Sarepta Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Sarepta Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Debt-to-Asset falls into.



Sarepta Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sarepta Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(113.092 + 1167.781) / 2993.616
=0.43

Sarepta Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(82.527 + 1176.683) / 3243.541
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sarepta Therapeutics  (STU:AB3A) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Sarepta Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Sarepta Therapeutics Headlines

No Headlines